Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

Inclusion criteria

• Diagnosis of melanoma (ICD-9 172x & ICD-10 C43 or D03x)
• ≥2 documented clinical encounters on different days in the Flatiron network on or after 01 January 2011
• Pathologic unresectable stage III or IV at initial diagnosis after 01 January 2011, or earlier stage disease accompanied by development of a first locoregional recurrence after 01 January 2011
• Diagnosis of MM after 01 January 2011
• Evidence of a BRAF-positive result at any point in time
• Treatment with one of the following 1L therapies on or after 01 January 2014:

• IO (nivolumab, pembrolizumab, or ipilimumab + nivolumab)
• TT (dab/tram)
• At least 18 years of age at the time of initiation of 1L therapy
• At least 6-months of continuous follow-up from the time of initiation of 1L therapy

Exclusion criteria

• Lacking relevant unstructured documents (i.e., information such as free text from a physician note or pathology report that is captured systematically during the data abstraction process) in the Flatiron Health database
• Evidence of non-skin melanoma (ocular, subungual, mucosal, palmar, plantar)
• Documented receipt of a clinical study drug, defined as any uncancelled order, administration, or oral episode for a clinical study drug for cancer at any time prior to or during 1L treatment
• Presence of leptomeningeal disease (ICD-9 198.4 & ICD-10 C79.32 or C79.49)